LINK Healthcare receives generic approval for TRANEXAMIC ACID Generic formulation used to reduce peri- and post-operative blood loss Latest addition to LINK’s growing specialist generic range of medicines Sydney/Pretoria/Singapore/Tokyo/Hong Kong/Auckland: 12th August 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has received Australian marketing approval for its generic

LINK Healthcare establishes regional platform for Early and Expanded Access Programs (EAPs) for the Australasian, Asian & African markets     EAPs make it possible to get vital and life-saving treatments to patients with no other option LINK has signed 12 regional EAP agreements in the last 12 months LINK’s territory covers 33% of the

LINK Healthcare receives “first to market” generic approval for Lignocaine HCl 5% & Phenylephrine HCl 0.5% topical Solution Generic formulation for nasal surgical procedures Latest addition to LINK’s growing generic range of specialist medicines Sydney/Pretoria/Singapore/Tokyo/Auckland: 14th July 2014   Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) announced today that it has received marketing

ASX ANNOUNCEMENT Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ‘Penthrox’ for pain relief from trauma and surgical procedures. The approval gives MVP’s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals

Link Healthcare secures marketing approval for ALLMERCAP™ for the treatment of acute lymphoblastic leukaemia (ALL) the product is an oral suspension of current ALL treatment, mercaptopurine ALLMERCAP’s child-friendly formulation offers more accurate dosing than tablets LINK has partnered with Nova Laboratories, UK to make the drug available in Australia Sydney/Pretoria/Singapore/Tokyo/Auckland: 16 June 2014. Specialist pharmaceutical

LINK Healthcare Partners With Sigma Tau Group For Regional Distribution Rights To Rare Disease Therapeutics • Exclusive agreement to distribute  in selected countries of  Africa, Asia and Australasia:  Oncaspar® for the treatment of acute lymphoblastic leukemia; Adagen® for adenosine deaminase-severe combined immunodeficiency disease and Cystaran™ for ocular cystinosis • Territory rights expanded for Natulan™ for the treatment

LINK Healthcare PTE LTD and photonamic GmbH & Co. KG sign a licensing agreement for Alacare®, a new therapeutic for the treatment of actinic keratosis. This licensing agreement gives LINK exclusive rights to market Alacare® in Australia, New Zealand and South Africa. Alacare® is a photodynamic therapeutic in the form of a medicated patch for

Melbourne, Australia, June 20th 2013: Australian biotechnology company Avexa Limited [ASX:AVX] today announced that it has signed a binding term sheet with Link Healthcare Pte Ltd (LINK) for the development and commercialization of Avexa’s lead HIV drug apricitabine (ATC). “Avexa is delighted to expand our collaboration with Link” said Mr Iain Kirkwood, Chairman of Avexa,

Link Healthcare Obtains Extensive Regional Rights To  Secrelux From Sanochemia Sydney/Pretoria/Singapore/Tokyo/Auckland: 14 May 2013. Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’) is pleased to announce that it has signed an agreement with Sanochemia Pharmazeutika AG for regional rights to Secrelux®, a pancreatic function diagnostic.LINK has been assigned the exclusive rights to Secrelux® for Australia, New

Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’), reports that one of its products, Colistin-Link, is gaining stature in the treatment of multi drug resistant bacteria. Today, infectious disease kills more people than cancer and so called “superbugs”, bacteria that don’t respond to antibiotics, are emerging as a major health threat. In a recent